Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

72
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
72
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

2.6K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.6K
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

91
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
91
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

405
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
405
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

767
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
767
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

88
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
88

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A protein interactome for the last eukaryotic common ancestor illuminates the biochemical basis of modern genetic diseases.

Cell genomics·2026
Same author

How variant discovery redefines genetic prevalence: the case of cystine stone disease.

European journal of human genetics : EJHG·2026
Same author

Precision Diagnosis in APOL1 Kidney Disease With the p.N264K M1 Protective Variant.

JAMA network open·2026
Same author

N<sup>6</sup>-adenosine methylation enhances nuclear mRNA export through METTL3 and NUP93.

Nature cell biology·2026
Same author

Identification of monogenic variants in steroid-resistant and steroid-sensitive nephrotic syndrome.

Pediatric nephrology (Berlin, Germany)·2026
Same author

Mechanisms of Podocyte Injury Due to Loss of the Nucleoporin NUP93.

Journal of the American Society of Nephrology : JASN·2026
Same journal

Urinary Soluble CD163: A Dynamic Biomarker for Monitoring Treatment Response and Relapse in IgA Nephropathy.

Kidney international reports·2026
Same journal

<i>APOL1</i> Variants, AKI, and Progression to Kidney Failure in People of African Ancestry Living with HIV.

Kidney international reports·2026
Same journal

Validation of the Standardized Outcomes in Nephrology - Life Participation (SONG-LP) Instrument in People Receiving Dialysis.

Kidney international reports·2026
Same journal

Effect of Hemodialysis With Citrate on Vascular Calcification.

Kidney international reports·2026
Same journal

Diagnostic Latency and Unmeasured Disease Severity in Male Lupus Nephritis.

Kidney international reports·2026
Same journal

Antinephrin, Antipodocin, and Anti-Kirrel1 Autoantibodies in Posttransplant Recurrent FSGS.

Kidney international reports·2026
See all related articles

Related Experiment Video

Updated: Apr 7, 2026

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications
09:39

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications

Published on: February 7, 2021

9.2K

NPHS2 Revisited Through 208 Cases and Podocin Complex Modeling.

Nils David Mertens1, Camille Nicolas Frank1, Leah Bolsius1

  • 1Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Kidney International Reports
|April 6, 2026
PubMed
Summary
This summary is machine-generated.

Steroid-resistant nephrotic syndrome (SRNS) is linked to NPHS2 gene variants. This study reveals genotype-phenotype correlations and proposes podocin

Keywords:
NPHS2 (podocin)genotype–phenotype correlationmonogenic kidney diseasepodocyte slit diaphragmsteroid-resistant nephrotic syndrome (SRNS)structural modeling

More Related Videos

Author Spotlight: Generation of Patient-Derived Podocytes from Skin Biopsies
08:52

Author Spotlight: Generation of Patient-Derived Podocytes from Skin Biopsies

Published on: May 26, 2023

3.3K
Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

2.0K

Related Experiment Videos

Last Updated: Apr 7, 2026

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications
09:39

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications

Published on: February 7, 2021

9.2K
Author Spotlight: Generation of Patient-Derived Podocytes from Skin Biopsies
08:52

Author Spotlight: Generation of Patient-Derived Podocytes from Skin Biopsies

Published on: May 26, 2023

3.3K
Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

2.0K

Area of Science:

  • Genetics
  • Molecular Biology
  • Nephrology

Background:

  • Steroid-resistant nephrotic syndrome (SRNS) is a major cause of chronic kidney disease in young individuals.
  • Biallelic variants in the NPHS2 gene, encoding podocin, are the most frequent monogenic cause of SRNS.
  • Understanding NPHS2 genotype-phenotype relationships and podocin's structure is crucial for diagnosis and treatment.

Purpose of the Study:

  • To investigate genotype-phenotype correlations in a large cohort of patients with NPHS2 variants.
  • To elucidate the higher-order assembly architecture of podocin using advanced structural modeling.
  • To improve the assessment of NPHS2 variants of unknown significance.

Main Methods:

  • Analysis of clinical data from 208 individuals with pathogenic NPHS2 variants.
  • Application of in silico pathogenicity prediction tools (REVEL, EVE) and evolutionary modeling.
  • High-order structural modeling using AlphaFold3 to predict podocin assembly architecture.

Main Results:

  • Identified a wide spectrum of NPHS2 allelic variants and variable disease onset.
  • Correlated specific genotypes (e.g., p.R229Q, p.V180M) with later disease onset.
  • Proposed a novel AI-generated model of podocin higher-order assemblies with variants clustering at oligomer interfaces.

Conclusions:

  • Delineated genotype-phenotype relationships for NPHS2-associated SRNS.
  • Proposed a structural model for podocin assemblies, aiding variant assessment.
  • Highlighted the need for experimental validation of structural findings.